Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease

Expert Opinion on Investigational Drugs

Volumn 19, Issue 2, 2010, Pages 257-264

  Joos, Guy F ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bronchodilators; Clinical trials; COPD; Muscarinic antagonists

Indexed keywords

ACLIDINIUM BROMIDE; FENOTEROL; FLUTICASONE; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; HANDIHALER; IPRATROPIUM BROMIDE; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG SAFETY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HUMAN; MONOTHERAPY; NONHUMAN; REVIEW; XEROSTOMIA;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ANDROSTADIENES; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, MUSCARINIC; SCOPOLAMINE DERIVATIVES;

EID: 74549139733     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903505084     Document Type: Review

References (53)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-555
2. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008;155(3):291-299
3. Joos G, Geppetti P. Neural mechanisms in asthma. Eur Respir Mon 2003; 23:138-163
4. Costello RW, Fryer AD. Cholinergic mechanisms in asthma. In: Barnes PJ, Grunstein MM, editors, Asthma. Lippincott-Raven, Philadelphia; 2003. p. 965-984
5. Barnes PJ. Muscarinic receptor subtypes in airways. Eur Respir J 1993;6(3):328-331
6. Gross NJ. Cholinergic antagonists. Kay AB, Kaplan AP, Bousquet J, Holt PG. In: Allergy and allergic diseases. Wiley-Blackwell Publishing; 2008. p. 683-693
7. Casarosa P, Bouyssou T, Germeyer S, et al. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational products. J Pharmacol Exp Ther 2009;330(2):660-668
8. Barnes PJ, Belvisi MG, Mak JC, et al. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 1995;56(11-12):853-859
9. Hvizdos KM, Goa KL. Tiotropium bromide. Drugs 2002;62(8):1195-1203
10. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117(2 Suppl):63S-6S
11. Maesen FP, Smeets JJ, Costongs MA, et al. Ba 679 Br, a new long-acting antimuscarinic bronchodilator: a pilot dose-escalation study in COPD. Eur Respir J 1993;6(7):1031-1036
12. Maesen FP, Smeets JJ, Sledsens TJ, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J 1995;8(9):1506-1513
13. van Noord JA, Smeets JJ, Custers FL, et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002;19(4):639-644
14. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161(4 Pt 1):1136-1142
15. Casaburi R, Briggs DD Jr, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000;118(5):1294-1302
16. van Noord JA, Bantje TA, Eland ME, et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55(4):289-294
17. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004;350(26):2689-2697
18. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23(6):832-840
19. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127:809-817
20. Casaburi R MD, Jones PW, Wanner A, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224
21. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003;123(5):1441-1449
22. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-216
23. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61(10):854-862
24. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-1554
25. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1129-1130
26. Caillaud D, Le Merre C, Martinat Y, et al. A dose-ranging study of tiotropium delivered via Respimat® Soft Mist® Inhaler or Handihaler® in COPD patients. Int J COPD 2009;2:559-565
27. van Noord JA, Cornelissen PJG, Aumann J-L, et al. The efficacy of tiotropium administered via Respimat® Soft Mist® Inhaler or Handihaler® in COPD patients. Respir Med 2009;103:22-29
28. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122(1):47-55
29. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005;26(2):214-222
30. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129(3):509-517
31. Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008;102(4):479-487
32. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono-and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008;102(11):1511-1520
33. Kerstjens HA, Bantje TA, Luursema PB, et al. Effects of short-acting bronchodilators added to maintenance tiotropium therapy. Chest 2007;132(5):1493-1499
34. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008;134(2):255-262
35. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177(1):19-26
36. Singh D, Brooks J, Hagan G, et al. Superiority of 'triple' therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63(7):592-598
37. Cazzola M, Ando F, Santus P, et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007;20(5):556-561
38. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146(8):545-555
39. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(12):1439-1450
40. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149(6):380-390
41. FDA. Drug safety communications. Drug Safety Newsletter 2009;2(1):10
42. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2009. [Epub ahead of print]
43. Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009;331:740-751
44. Jansat JM, Lamarca R, Garcia Gil E, Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 2009;47:460-468
45. Jansat JM, Lamarca R, de Miquel G, et al. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol 2009;49:1239-1246
46. Schelfhout VJ, Ferrer P, Jansat JM, et al. Activity of aclidinium bromide, a new long-acting anticholinergic agent: a phase I study. Br J Clin Pharmacol 2009 [accepted]
47. Joos GF, Schelfhout VJ, Kanniess F, et al. Bronchodilatory effect of aclidinium bromide, a long-lasting anticholinergic, in COPD patients. Respir Med 2009 [accepted]
48. Chanez P, Burge PS, Dahl R, et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther 2009. [Epub ahead of print]
49. Hansel TT, Neighbour H, Erin EM, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005;128(4):1974-1979
50. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009;34:757-769
51. Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007;30(3):472-478
52. Matthiesen S, Bahulayan A, Kempkens S, et al. Muscarinic receptors mediate stimulation of human lung fibroblast proliferation. Am J Respir Cell Mol Biol 2006;35(6):621-627
53. Haag S, Matthiesen S, Juergens UR, Racke K. Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts. Eur Respir J 2008;32:555-562